ClinicaliQ Trial Snapshot
- Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) — Active Not Recruiting • Phase III • Oncology • NCT04793958.
- MRTX849 plus cetuximab compared to chemotherapy for advanced bowel cancer with specific KRAS mutation.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation. Conditions: Advanced Colorectal Cancer, Metastatic Colorectal Cancer Interventions: MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen Lead Sponsor: Mirati Therapeutics Inc. Planned Enrollment: 461 participants